CARL ZEISS MEDITEC AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.25 EUR | 0.00% |
|
-3.00% | -32.90% |
| 06-24 | RBC lowers target for Carl Zeiss Meditec to 85 euros - 'Outperform' | DP |
| 06-24 | UBS lowers Carl Zeiss Meditec to 'Neutral' - target to 71 euros | DP |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.03 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -32.90% | 6.41B | - | ||
| +4.85% | 216B | B | ||
| +9.86% | 190B | B- | ||
| +31.11% | 152B | B- | ||
| +34.08% | 113B | A- | ||
| +1.90% | 64.04B | A- | ||
| +19.45% | 54.34B | B+ | ||
| +1.63% | 49.21B | B+ | ||
| -3.12% | 39.41B | A | ||
| +1.93% | 35.99B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AFX Stock
- AFX Stock
- Ratings Carl Zeiss Meditec AG
